Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 18 | 2025 | 357 | 2.260 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2025 | 193 | 1.420 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2025 | 94 | 1.390 |
Why?
|
| Graft vs Host Disease | 7 | 2025 | 113 | 1.240 |
Why?
|
| Transplantation Conditioning | 10 | 2018 | 101 | 0.820 |
Why?
|
| Multiple Myeloma | 8 | 2025 | 375 | 0.730 |
Why?
|
| Clostridium Infections | 1 | 2022 | 49 | 0.710 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2026 | 54 | 0.500 |
Why?
|
| Leukemia | 2 | 2016 | 62 | 0.480 |
Why?
|
| Transplantation, Homologous | 8 | 2025 | 250 | 0.390 |
Why?
|
| Myeloablative Agonists | 3 | 2015 | 12 | 0.330 |
Why?
|
| Dendritic Cells | 1 | 2013 | 534 | 0.300 |
Why?
|
| Mutation | 5 | 2025 | 2674 | 0.300 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2020 | 14 | 0.270 |
Why?
|
| Mitoxantrone | 2 | 2018 | 16 | 0.260 |
Why?
|
| Aged | 23 | 2026 | 15147 | 0.260 |
Why?
|
| Amyloidosis | 2 | 2020 | 70 | 0.260 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2019 | 70 | 0.250 |
Why?
|
| Busulfan | 2 | 2018 | 18 | 0.250 |
Why?
|
| Adult | 22 | 2025 | 17579 | 0.250 |
Why?
|
| Lymphoma, Follicular | 1 | 2026 | 18 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2026 | 378 | 0.240 |
Why?
|
| Disease-Free Survival | 9 | 2017 | 245 | 0.230 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2026 | 67 | 0.230 |
Why?
|
| Stem Cell Transplantation | 3 | 2020 | 79 | 0.230 |
Why?
|
| Humans | 36 | 2026 | 65843 | 0.220 |
Why?
|
| Multimorbidity | 1 | 2025 | 54 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 198 | 0.220 |
Why?
|
| Melphalan | 2 | 2015 | 23 | 0.220 |
Why?
|
| Male | 26 | 2026 | 31410 | 0.220 |
Why?
|
| Aged, 80 and over | 12 | 2025 | 5682 | 0.210 |
Why?
|
| Staurosporine | 1 | 2024 | 19 | 0.200 |
Why?
|
| Dioxygenases | 1 | 2024 | 36 | 0.200 |
Why?
|
| Female | 26 | 2026 | 34424 | 0.200 |
Why?
|
| Middle Aged | 21 | 2026 | 18501 | 0.200 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 184 | 0.200 |
Why?
|
| Algorithms | 2 | 2026 | 1060 | 0.190 |
Why?
|
| Electronic Health Records | 1 | 2026 | 398 | 0.180 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 403 | 0.180 |
Why?
|
| Transplantation, Autologous | 6 | 2020 | 128 | 0.180 |
Why?
|
| Treatment Outcome | 11 | 2025 | 5834 | 0.170 |
Why?
|
| Cyclophosphamide | 2 | 2025 | 84 | 0.160 |
Why?
|
| Incidence | 2 | 2022 | 1433 | 0.160 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 136 | 0.160 |
Why?
|
| Strongyloides stercoralis | 1 | 2020 | 12 | 0.160 |
Why?
|
| Strongyloidiasis | 1 | 2020 | 10 | 0.160 |
Why?
|
| Survival Analysis | 6 | 2018 | 579 | 0.160 |
Why?
|
| Child | 5 | 2022 | 4652 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 104 | 0.150 |
Why?
|
| Adolescent | 11 | 2018 | 6368 | 0.150 |
Why?
|
| Retrospective Studies | 6 | 2022 | 6957 | 0.140 |
Why?
|
| Survival Rate | 5 | 2025 | 849 | 0.140 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 44 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 45 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 256 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 50 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 2 | 2016 | 140 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1226 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 645 | 0.130 |
Why?
|
| Vascular Diseases | 1 | 2018 | 83 | 0.130 |
Why?
|
| Young Adult | 8 | 2025 | 4883 | 0.130 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2017 | 19 | 0.130 |
Why?
|
| Databases, Factual | 5 | 2021 | 888 | 0.130 |
Why?
|
| Allografts | 4 | 2018 | 47 | 0.120 |
Why?
|
| Virus Activation | 1 | 2016 | 23 | 0.120 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2016 | 28 | 0.120 |
Why?
|
| Leukapheresis | 1 | 2015 | 11 | 0.120 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2015 | 16 | 0.110 |
Why?
|
| Leukocytosis | 1 | 2015 | 15 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 33 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 1 | 2016 | 68 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 466 | 0.110 |
Why?
|
| Cytomegalovirus | 1 | 2016 | 94 | 0.110 |
Why?
|
| Metabolic Syndrome | 1 | 2016 | 147 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 171 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2015 | 210 | 0.100 |
Why?
|
| Whole-Body Irradiation | 2 | 2014 | 34 | 0.100 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2014 | 35 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 113 | 0.100 |
Why?
|
| Recurrence | 4 | 2017 | 665 | 0.100 |
Why?
|
| Bone Marrow | 1 | 2014 | 178 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 24 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2020 | 274 | 0.090 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 52 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2017 | 2116 | 0.090 |
Why?
|
| Quality of Life | 1 | 2018 | 1266 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 196 | 0.080 |
Why?
|
| Infant | 4 | 2018 | 1717 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 286 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 420 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 527 | 0.080 |
Why?
|
| Child, Preschool | 4 | 2018 | 2089 | 0.080 |
Why?
|
| Parotitis | 1 | 2009 | 1 | 0.070 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2024 | 26 | 0.070 |
Why?
|
| Anemia, Aplastic | 1 | 2009 | 10 | 0.070 |
Why?
|
| Lymphocyte Transfusion | 1 | 2009 | 37 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 878 | 0.070 |
Why?
|
| Comorbidity | 2 | 2025 | 1122 | 0.070 |
Why?
|
| Registries | 2 | 2026 | 935 | 0.070 |
Why?
|
| Remission Induction | 2 | 2018 | 149 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2009 | 304 | 0.060 |
Why?
|
| Age Factors | 3 | 2018 | 1595 | 0.060 |
Why?
|
| Risk Factors | 4 | 2018 | 5475 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 161 | 0.060 |
Why?
|
| Prognosis | 2 | 2025 | 1793 | 0.060 |
Why?
|
| Disease Progression | 2 | 2024 | 1229 | 0.060 |
Why?
|
| SEER Program | 1 | 2025 | 76 | 0.060 |
Why?
|
| Stem Cells | 1 | 2007 | 278 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 35 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 375 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 82 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 316 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 344 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2024 | 351 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2021 | 51 | 0.040 |
Why?
|
| Electronics | 1 | 2021 | 34 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1391 | 0.040 |
Why?
|
| Medicare | 1 | 2025 | 629 | 0.040 |
Why?
|
| Bortezomib | 1 | 2020 | 60 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2020 | 52 | 0.040 |
Why?
|
| Thiabendazole | 1 | 2020 | 3 | 0.040 |
Why?
|
| Enterococcus faecium | 1 | 2020 | 7 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2020 | 14 | 0.040 |
Why?
|
| Daptomycin | 1 | 2020 | 9 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2020 | 33 | 0.040 |
Why?
|
| Antiparasitic Agents | 1 | 2020 | 10 | 0.040 |
Why?
|
| Ivermectin | 1 | 2020 | 25 | 0.040 |
Why?
|
| Abdomen | 1 | 2020 | 97 | 0.040 |
Why?
|
| Imatinib Mesylate | 1 | 2019 | 34 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2020 | 88 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 314 | 0.040 |
Why?
|
| Neoplasms | 1 | 2009 | 1378 | 0.030 |
Why?
|
| Autografts | 1 | 2017 | 9 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 163 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 3779 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2016 | 17 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 32 | 0.030 |
Why?
|
| Probability | 1 | 2017 | 170 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 28 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2016 | 26 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 60 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 13 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 108 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 221 | 0.030 |
Why?
|
| Karyotype | 1 | 2015 | 18 | 0.030 |
Why?
|
| Respiration Disorders | 1 | 2015 | 26 | 0.030 |
Why?
|
| Cell Size | 1 | 2015 | 41 | 0.030 |
Why?
|
| Siblings | 1 | 2014 | 41 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 995 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2014 | 8 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 78 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2016 | 346 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 329 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 371 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1172 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2016 | 332 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 25 | 0.020 |
Why?
|
| Cytarabine | 1 | 2012 | 36 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2012 | 35 | 0.020 |
Why?
|
| Echocardiography | 1 | 2016 | 513 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 463 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 208 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 899 | 0.020 |
Why?
|
| United States | 1 | 2025 | 8189 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 932 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 1719 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1117 | 0.020 |
Why?
|
| Massachusetts | 1 | 2016 | 2158 | 0.020 |
Why?
|
| Transplantation Chimera | 1 | 2009 | 41 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 63 | 0.020 |
Why?
|
| Prednisone | 1 | 2009 | 83 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1569 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2009 | 187 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 2651 | 0.020 |
Why?
|
| Heart Failure | 1 | 2016 | 968 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 169 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 559 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2007 | 19 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 3340 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 185 | 0.020 |
Why?
|
| S Phase | 1 | 2007 | 79 | 0.020 |
Why?
|
| Interphase | 1 | 2007 | 68 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 21492 | 0.020 |
Why?
|
| Pluripotent Stem Cells | 1 | 2007 | 72 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 993 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 237 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 157 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 195 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2007 | 282 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2007 | 398 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 2500 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2007 | 1561 | 0.010 |
Why?
|
| Mice | 1 | 2007 | 11184 | 0.010 |
Why?
|